KR20060123364A - 니코틴성 아세틸콜린 수용체 리간드 - Google Patents
니코틴성 아세틸콜린 수용체 리간드 Download PDFInfo
- Publication number
- KR20060123364A KR20060123364A KR1020067012362A KR20067012362A KR20060123364A KR 20060123364 A KR20060123364 A KR 20060123364A KR 1020067012362 A KR1020067012362 A KR 1020067012362A KR 20067012362 A KR20067012362 A KR 20067012362A KR 20060123364 A KR20060123364 A KR 20060123364A
- Authority
- KR
- South Korea
- Prior art keywords
- disease
- methanone
- oct
- disorder
- diazabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title claims description 24
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title claims description 24
- 239000003446 ligand Substances 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 95
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 230000002265 prevention Effects 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000004434 sulfur atom Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- -1 1-methyl-1H-pyrrolyl Chemical group 0.000 claims description 10
- 229960002715 nicotine Drugs 0.000 claims description 10
- 208000028017 Psychotic disease Diseases 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 8
- 208000016620 Tourette disease Diseases 0.000 claims description 8
- 230000036506 anxiety Effects 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 208000000044 Amnesia Diseases 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 208000026139 Memory disease Diseases 0.000 claims description 7
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 7
- 230000009286 beneficial effect Effects 0.000 claims description 7
- 230000001713 cholinergic effect Effects 0.000 claims description 7
- 235000019788 craving Nutrition 0.000 claims description 7
- 230000006735 deficit Effects 0.000 claims description 7
- 230000006984 memory degeneration Effects 0.000 claims description 7
- 208000023060 memory loss Diseases 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 7
- 230000036407 pain Effects 0.000 claims description 7
- 230000005586 smoking cessation Effects 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 230000003935 attention Effects 0.000 claims description 6
- 230000007278 cognition impairment Effects 0.000 claims description 6
- 206010026749 Mania Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 206010068887 Tobacco poisoning Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 210000000225 synapse Anatomy 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 206010027951 Mood swings Diseases 0.000 claims description 3
- 206010057852 Nicotine dependence Diseases 0.000 claims description 3
- DPTARYYFKCRQTE-CURYUGHLSA-N [(5r)-1,4-diazabicyclo[3.2.1]octan-4-yl]-(5-pyridin-3-yl-1,3-oxazol-2-yl)methanone;dihydrochloride Chemical compound Cl.Cl.C([C@@]1(C2)[H])CN2CCN1C(=O)C(O1)=NC=C1C1=CC=CN=C1 DPTARYYFKCRQTE-CURYUGHLSA-N 0.000 claims description 3
- 230000007470 synaptic degeneration Effects 0.000 claims description 3
- XCGBGBFIBJGCFK-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octan-4-yl(1h-indol-5-yl)methanone Chemical compound C1=C2NC=CC2=CC(C(N2C3CCN(C3)CC2)=O)=C1 XCGBGBFIBJGCFK-UHFFFAOYSA-N 0.000 claims description 2
- JPYPFWJCVOBZFC-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octan-4-yl(naphthalen-2-yl)methanone Chemical compound C1=CC=CC2=CC(C(N3C4CCN(C4)CC3)=O)=CC=C21 JPYPFWJCVOBZFC-UHFFFAOYSA-N 0.000 claims description 2
- SRRYXXRXYHWRCC-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octan-4-yl-(1-methylindol-2-yl)methanone Chemical compound C1CN(C2)CCC2N1C(=O)C1=CC2=CC=CC=C2N1C SRRYXXRXYHWRCC-UHFFFAOYSA-N 0.000 claims description 2
- DOQNLHXQIXLQHV-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octan-4-yl-(3-phenylphenyl)methanone Chemical compound C1CN(C2)CCC2N1C(=O)C(C=1)=CC=CC=1C1=CC=CC=C1 DOQNLHXQIXLQHV-UHFFFAOYSA-N 0.000 claims description 2
- BBBGZUNBNLXJDW-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octan-4-yl-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(C2)CCN2CC1 BBBGZUNBNLXJDW-UHFFFAOYSA-N 0.000 claims description 2
- YAJCHOBSJSFSJL-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octan-4-yl-(5-phenylfuran-2-yl)methanone Chemical compound C1CN(C2)CCC2N1C(=O)C(O1)=CC=C1C1=CC=CC=C1 YAJCHOBSJSFSJL-UHFFFAOYSA-N 0.000 claims description 2
- YIDVOMHIXSRHJP-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octan-4-yl-(5-phenylthiophen-2-yl)methanone Chemical compound C1CN(C2)CCC2N1C(=O)C(S1)=CC=C1C1=CC=CC=C1 YIDVOMHIXSRHJP-UHFFFAOYSA-N 0.000 claims description 2
- PMDQATSTNUQJNH-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octan-4-yl-(5-pyridin-3-ylthiophen-2-yl)methanone Chemical compound C1CN(C2)CCC2N1C(=O)C(S1)=CC=C1C1=CC=CN=C1 PMDQATSTNUQJNH-UHFFFAOYSA-N 0.000 claims description 2
- PUHROTZEKWXENT-UHFFFAOYSA-N 1-benzofuran-2-yl(1,4-diazabicyclo[3.2.1]octan-4-yl)methanone Chemical compound C1=CC=C2OC(C(N3C4CCN(C4)CC3)=O)=CC2=C1 PUHROTZEKWXENT-UHFFFAOYSA-N 0.000 claims description 2
- IBUKGKXJAFMRGQ-MRXNPFEDSA-N 3-[5-[(5r)-1,4-diazabicyclo[3.2.1]octane-4-carbonyl]thiophen-2-yl]-n,n-dimethylbenzamide Chemical compound C([C@@]1(C2)[H])CN2CCN1C(=O)C(S1)=CC=C1C1=CC=CC(C(=O)N(C)C)=C1 IBUKGKXJAFMRGQ-MRXNPFEDSA-N 0.000 claims description 2
- KDBYJAZTZNYSLV-MRXNPFEDSA-N 4-[5-[(5r)-1,4-diazabicyclo[3.2.1]octane-4-carbonyl]thiophen-2-yl]-n,n-dimethylbenzamide Chemical compound C([C@@]1(C2)[H])CN2CCN1C(=O)C(S1)=CC=C1C1=CC=C(C(=O)N(C)C)C=C1 KDBYJAZTZNYSLV-MRXNPFEDSA-N 0.000 claims description 2
- 201000006347 Intellectual Disability Diseases 0.000 claims description 2
- ZLSKRDYRWRJPKZ-BTQNPOSSSA-N [(5r)-1,4-diazabicyclo[3.2.1]octan-4-yl]-(5-phenyl-1,3-oxazol-2-yl)methanone;hydrochloride Chemical compound Cl.C([C@@]1(C2)[H])CN2CCN1C(=O)C(O1)=NC=C1C1=CC=CC=C1 ZLSKRDYRWRJPKZ-BTQNPOSSSA-N 0.000 claims description 2
- GPSANNSGFOQYQJ-GFCCVEGCSA-N [(5r)-1,4-diazabicyclo[3.2.1]octan-4-yl]-(5-pyridin-4-yl-1,3-oxazol-2-yl)methanone Chemical compound C([C@@]1(C2)[H])CN2CCN1C(=O)C(O1)=NC=C1C1=CC=NC=C1 GPSANNSGFOQYQJ-GFCCVEGCSA-N 0.000 claims description 2
- SYIQLHYXTUKKPA-UHFFFAOYSA-N [5-(4-chlorophenyl)furan-2-yl]-(1,4-diazabicyclo[3.2.1]octan-4-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C(=O)N2C3CCN(C3)CC2)O1 SYIQLHYXTUKKPA-UHFFFAOYSA-N 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract 1
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- 239000000203 mixture Substances 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- 239000007787 solid Substances 0.000 description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 239000010410 layer Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229910052722 tritium Inorganic materials 0.000 description 10
- KTQXJRSTWRKYOU-UHFFFAOYSA-N 1,2-diazabicyclo[3.2.1]octane;dihydrochloride Chemical compound Cl.Cl.C1C2CCN1NCC2 KTQXJRSTWRKYOU-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- CTBNEKSAJTWOFM-QYCVXMPOSA-N (5r)-1,4-diazabicyclo[3.2.1]octane;dihydrochloride Chemical compound Cl.Cl.C1N2CC[C@@]1([H])NCC2 CTBNEKSAJTWOFM-QYCVXMPOSA-N 0.000 description 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 5
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 4
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- OFMCORUCLRVDQI-UHFFFAOYSA-N 2-amino-1-pyridin-3-ylethanone;dihydrochloride Chemical compound Cl.Cl.NCC(=O)C1=CC=CN=C1 OFMCORUCLRVDQI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- HNYRNJAZRKCHSC-UHFFFAOYSA-N ethyl 2-(3-oxopiperazin-2-yl)acetate Chemical compound CCOC(=O)CC1NCCNC1=O HNYRNJAZRKCHSC-UHFFFAOYSA-N 0.000 description 3
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 3
- BITIKWHSAXIQPV-UHFFFAOYSA-M lithium;5-phenyl-1,3-oxazole-2-carboxylate Chemical compound [Li+].O1C(C(=O)[O-])=NC=C1C1=CC=CC=C1 BITIKWHSAXIQPV-UHFFFAOYSA-M 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YEOULXNUCBERTD-QYCVXMPOSA-N (2r)-2-(2-chloroethyl)piperazine;dihydrochloride Chemical compound Cl.Cl.ClCC[C@@H]1CNCCN1 YEOULXNUCBERTD-QYCVXMPOSA-N 0.000 description 2
- KYCAEEFYFFBAAP-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octane Chemical compound C1C2CCN1CCN2 KYCAEEFYFFBAAP-UHFFFAOYSA-N 0.000 description 2
- CTBNEKSAJTWOFM-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.1]octane;dihydrochloride Chemical compound Cl.Cl.C1C2CCN1CCN2 CTBNEKSAJTWOFM-UHFFFAOYSA-N 0.000 description 2
- OFFSPAZVIVZPHU-UHFFFAOYSA-N 1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- YIYKZUCYKKNQFH-CYBMUJFWSA-N 2-[(2r)-4-benzylpiperazin-2-yl]ethanol Chemical compound C1CN[C@H](CCO)CN1CC1=CC=CC=C1 YIYKZUCYKKNQFH-CYBMUJFWSA-N 0.000 description 2
- DSSFSAGQNGRBOR-ZCFIWIBFSA-N 2-[(2r)-piperazin-2-yl]ethanol Chemical compound OCC[C@@H]1CNCCN1 DSSFSAGQNGRBOR-ZCFIWIBFSA-N 0.000 description 2
- DSSFSAGQNGRBOR-UHFFFAOYSA-N 2-piperazin-2-ylethanol Chemical compound OCCC1CNCCN1 DSSFSAGQNGRBOR-UHFFFAOYSA-N 0.000 description 2
- QUSZQTKCRWUCTP-UHFFFAOYSA-N 4-(5-bromothiophen-2-yl)-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C1=CC=C(Br)S1 QUSZQTKCRWUCTP-UHFFFAOYSA-N 0.000 description 2
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- 101000783401 Bungarus multicinctus Alpha-bungarotoxin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- HYGWNUKOUCZBND-UHFFFAOYSA-N azanide Chemical compound [NH2-] HYGWNUKOUCZBND-UHFFFAOYSA-N 0.000 description 2
- YMTAXCIGHFWDLA-QGZVFWFLSA-N benzyl 2-[(2r)-4-benzyl-3,6-dioxopiperazin-2-yl]acetate Chemical compound N([C@@H](C1=O)CC(=O)OCC=2C=CC=CC=2)C(=O)CN1CC1=CC=CC=C1 YMTAXCIGHFWDLA-QGZVFWFLSA-N 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- FJIIFNUNDAWHGH-UHFFFAOYSA-N ethyl 2-oxo-2-(phenacylamino)acetate Chemical compound CCOC(=O)C(=O)NCC(=O)C1=CC=CC=C1 FJIIFNUNDAWHGH-UHFFFAOYSA-N 0.000 description 2
- CRCZQDUKNHUANZ-UHFFFAOYSA-N ethyl 2-oxo-2-[(2-oxo-2-pyridin-3-ylethyl)amino]acetate Chemical compound CCOC(=O)C(=O)NCC(=O)C1=CC=CN=C1 CRCZQDUKNHUANZ-UHFFFAOYSA-N 0.000 description 2
- CJFDXBPYBZFHBH-UHFFFAOYSA-N ethyl 5-[4-(dimethylcarbamoyl)phenyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OCC)=CC=C1C1=CC=C(C(=O)N(C)C)C=C1 CJFDXBPYBZFHBH-UHFFFAOYSA-N 0.000 description 2
- LRQAQFQUJNFEDT-UHFFFAOYSA-N ethyl 5-phenyl-1,3-oxazole-2-carboxylate Chemical compound O1C(C(=O)OCC)=NC=C1C1=CC=CC=C1 LRQAQFQUJNFEDT-UHFFFAOYSA-N 0.000 description 2
- UZIFAALLGSBVPJ-UHFFFAOYSA-N ethyl 5-pyridin-3-yl-1,3-oxazole-2-carboxylate Chemical compound O1C(C(=O)OCC)=NC=C1C1=CC=CN=C1 UZIFAALLGSBVPJ-UHFFFAOYSA-N 0.000 description 2
- DQEVAULOAYGIFN-UHFFFAOYSA-N ethyl 5-pyridin-4-yl-1,3-oxazole-2-carboxylate Chemical compound O1C(C(=O)OCC)=NC=C1C1=CC=NC=C1 DQEVAULOAYGIFN-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- UPCPRZXXEFEVDU-UHFFFAOYSA-M lithium;5-pyridin-3-yl-1,3-oxazole-2-carboxylate Chemical compound [Li+].O1C(C(=O)[O-])=NC=C1C1=CC=CN=C1 UPCPRZXXEFEVDU-UHFFFAOYSA-M 0.000 description 2
- UXLVMGOQKYLCDQ-UHFFFAOYSA-M lithium;5-pyridin-4-yl-1,3-oxazole-2-carboxylate Chemical compound [Li+].O1C(C(=O)[O-])=NC=C1C1=CC=NC=C1 UXLVMGOQKYLCDQ-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WSFAFVYGSMIUCY-UHFFFAOYSA-N tert-butyl n-(2-oxo-2-pyridin-3-ylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC(=O)C1=CC=CN=C1 WSFAFVYGSMIUCY-UHFFFAOYSA-N 0.000 description 2
- YIUGRGNVKORTOL-UHFFFAOYSA-N tert-butyl n-(2-oxo-2-pyridin-4-ylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC(=O)C1=CC=NC=C1 YIUGRGNVKORTOL-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- SOHLZANWVLCPHK-GFCCVEGCSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC(=O)OCC1=CC=CC=C1 SOHLZANWVLCPHK-GFCCVEGCSA-N 0.000 description 1
- KYCAEEFYFFBAAP-ZCFIWIBFSA-N (5r)-1,4-diazabicyclo[3.2.1]octane Chemical compound C1[C@H]2CCN1CCN2 KYCAEEFYFFBAAP-ZCFIWIBFSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 229930182840 (S)-nicotine Natural products 0.000 description 1
- RDJUHLUBPADHNP-UHFFFAOYSA-N 1,2,3,5-tetrahydroxybenzene Chemical compound OC1=CC(O)=C(O)C(O)=C1 RDJUHLUBPADHNP-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- XNLWJFYYOIRPIO-UHFFFAOYSA-N 3-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 XNLWJFYYOIRPIO-UHFFFAOYSA-N 0.000 description 1
- UDFORAXSNZZHCQ-UHFFFAOYSA-N 3h-indole-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)=NC2=C1 UDFORAXSNZZHCQ-UHFFFAOYSA-N 0.000 description 1
- DKXDRPDEUZJVEZ-UHFFFAOYSA-N 3h-indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CCC2=C1 DKXDRPDEUZJVEZ-UHFFFAOYSA-N 0.000 description 1
- XGUHVHHJBSMNAG-UHFFFAOYSA-N 4-amino-n-(4-fluorophenyl)benzamide Chemical compound C1=CC(N)=CC=C1C(=O)NC1=CC=C(F)C=C1 XGUHVHHJBSMNAG-UHFFFAOYSA-N 0.000 description 1
- MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 1
- XIPQHWUSDHTXOO-UHFFFAOYSA-N 5-(4-chlorophenyl)furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C1=CC=C(Cl)C=C1 XIPQHWUSDHTXOO-UHFFFAOYSA-N 0.000 description 1
- GUOMINFEASCICM-UHFFFAOYSA-N 5-phenylfuran-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C1=CC=CC=C1 GUOMINFEASCICM-UHFFFAOYSA-N 0.000 description 1
- QGMFBCDNJUZQBZ-UHFFFAOYSA-N 5-phenylthiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=CC=C1 QGMFBCDNJUZQBZ-UHFFFAOYSA-N 0.000 description 1
- HQULGJDHOPDURG-UHFFFAOYSA-N 5-pyridin-2-ylthiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=CC=N1 HQULGJDHOPDURG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 0 NN*C(*1C(CC2)C*2CC1)=O Chemical compound NN*C(*1C(CC2)C*2CC1)=O 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- XOPYMEDZSUNSLC-CURYUGHLSA-N [(5r)-1,4-diazabicyclo[3.2.1]octan-4-yl]-(5-pyridin-4-yl-1,3-oxazol-2-yl)methanone;dihydrochloride Chemical compound Cl.Cl.C([C@@]1(C2)[H])CN2CCN1C(=O)C(O1)=NC=C1C1=CC=NC=C1 XOPYMEDZSUNSLC-CURYUGHLSA-N 0.000 description 1
- ODRUMEWBZGEQCB-UHFFFAOYSA-N [4-(dimethylcarbamoyl)phenoxy]boronic acid Chemical compound CN(C(=O)C1=CC=C(C=C1)OB(O)O)C ODRUMEWBZGEQCB-UHFFFAOYSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000003683 electrophilic halogenation reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBEUXQCPRQTIGW-UHFFFAOYSA-M lithium;5-[4-(dimethylcarbamoyl)phenyl]thiophene-2-carboxylate Chemical compound [Li+].C1=CC(C(=O)N(C)C)=CC=C1C1=CC=C(C([O-])=O)S1 UBEUXQCPRQTIGW-UHFFFAOYSA-M 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XWCCTMBMQUCLSI-UHFFFAOYSA-N n-ethyl-n-propylpropan-1-amine Chemical compound CCCN(CC)CCC XWCCTMBMQUCLSI-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000008019 pharmaceutical lubricant Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- CVXGFPPAIUELDV-UHFFFAOYSA-N phenacylazanium;chloride Chemical compound [Cl-].[NH3+]CC(=O)C1=CC=CC=C1 CVXGFPPAIUELDV-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53171003P | 2003-12-22 | 2003-12-22 | |
| US60/531,710 | 2003-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060123364A true KR20060123364A (ko) | 2006-12-01 |
Family
ID=34710245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067012362A Withdrawn KR20060123364A (ko) | 2003-12-22 | 2004-12-20 | 니코틴성 아세틸콜린 수용체 리간드 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070249588A1 (https=) |
| EP (1) | EP1699801A1 (https=) |
| JP (1) | JP2007515479A (https=) |
| KR (1) | KR20060123364A (https=) |
| CN (1) | CN1918166A (https=) |
| AR (1) | AR047337A1 (https=) |
| AU (1) | AU2004303738A1 (https=) |
| BR (1) | BRPI0417946A (https=) |
| CA (1) | CA2550655A1 (https=) |
| IL (1) | IL175993A0 (https=) |
| MX (1) | MXPA06007027A (https=) |
| NO (1) | NO20063354L (https=) |
| RU (1) | RU2006125636A (https=) |
| TW (1) | TW200529860A (https=) |
| UY (1) | UY28687A1 (https=) |
| WO (1) | WO2005061510A1 (https=) |
| ZA (1) | ZA200605027B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202430D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| SE0202465D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| RU2389729C2 (ru) * | 2003-12-22 | 2010-05-20 | Мемори Фармасьютиклз Корпорейшн | 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение |
| FR2865208B1 (fr) * | 2004-01-16 | 2009-01-16 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique |
| US20120071469A1 (en) * | 2009-05-14 | 2012-03-22 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators |
| AR077428A1 (es) | 2009-07-29 | 2011-08-24 | Sanofi Aventis | (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos |
| JP5996532B2 (ja) * | 2010-07-15 | 2016-09-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 有害生物防除剤としての新規複素環式化合物 |
| BR112013009823A2 (pt) | 2010-10-22 | 2016-07-05 | Bayer Ip Gmbh | novos compostos heterocíclicos como pesticidas |
| SG11201407919WA (en) | 2012-05-31 | 2014-12-30 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| JP2023512366A (ja) | 2020-02-03 | 2023-03-27 | ジェンザイム・コーポレーション | リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法 |
| AU2021311131B2 (en) | 2020-07-24 | 2026-02-19 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3281423A (en) * | 1964-02-03 | 1966-10-25 | Merck & Co Inc | 1, 3-ethanopiperazines and process |
| US5679673A (en) * | 1992-09-24 | 1997-10-21 | The United States Of America, Represented By The Department Of Health And Human Services | Aralkyl bridged diazabicycloalkane derivatives for CNS disorders |
| FR2791678B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| ATE348829T1 (de) * | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
| SE0202430D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| SE0202465D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| DE602004023586D1 (de) * | 2003-02-27 | 2009-11-26 | Neurosearch As | Neue diazabicyclische arylderivate |
-
2004
- 2004-12-08 TW TW093137975A patent/TW200529860A/zh unknown
- 2004-12-20 AU AU2004303738A patent/AU2004303738A1/en not_active Abandoned
- 2004-12-20 WO PCT/SE2004/001941 patent/WO2005061510A1/en not_active Ceased
- 2004-12-20 EP EP04809114A patent/EP1699801A1/en not_active Withdrawn
- 2004-12-20 MX MXPA06007027A patent/MXPA06007027A/es unknown
- 2004-12-20 CN CNA2004800412947A patent/CN1918166A/zh active Pending
- 2004-12-20 US US10/583,576 patent/US20070249588A1/en not_active Abandoned
- 2004-12-20 RU RU2006125636/04A patent/RU2006125636A/ru not_active Application Discontinuation
- 2004-12-20 CA CA002550655A patent/CA2550655A1/en not_active Abandoned
- 2004-12-20 JP JP2006546909A patent/JP2007515479A/ja active Pending
- 2004-12-20 BR BRPI0417946-3A patent/BRPI0417946A/pt not_active IP Right Cessation
- 2004-12-20 KR KR1020067012362A patent/KR20060123364A/ko not_active Withdrawn
- 2004-12-20 UY UY28687A patent/UY28687A1/es not_active Application Discontinuation
- 2004-12-20 AR ARP040104802A patent/AR047337A1/es not_active Application Discontinuation
-
2006
- 2006-05-29 IL IL175993A patent/IL175993A0/en unknown
- 2006-06-19 ZA ZA200605027A patent/ZA200605027B/en unknown
- 2006-07-19 NO NO20063354A patent/NO20063354L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06007027A (es) | 2006-08-31 |
| AR047337A1 (es) | 2006-01-18 |
| US20070249588A1 (en) | 2007-10-25 |
| TW200529860A (en) | 2005-09-16 |
| AU2004303738A1 (en) | 2005-07-07 |
| CA2550655A1 (en) | 2005-07-07 |
| RU2006125636A (ru) | 2008-01-27 |
| ZA200605027B (en) | 2007-12-27 |
| EP1699801A1 (en) | 2006-09-13 |
| UY28687A1 (es) | 2005-07-29 |
| IL175993A0 (en) | 2006-10-05 |
| BRPI0417946A (pt) | 2007-04-17 |
| NO20063354L (no) | 2006-09-21 |
| JP2007515479A (ja) | 2007-06-14 |
| CN1918166A (zh) | 2007-02-21 |
| WO2005061510A1 (en) | 2005-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1539764B1 (en) | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists. | |
| ES2316848T3 (es) | Biaril diazabicicloalcano amidas como agonistas de nicotinicos de la acetilcolina. | |
| AU2020343681A1 (en) | Heterocyclic RIP1 kinase inhibitors | |
| CA3104377C (en) | Heterocyclic compounds as trk inhibitors | |
| SK21697A3 (en) | Spiro-azabicyclic compounds useful in therapy | |
| CZ20021692A3 (cs) | Nové N-azabicykloamidové deriváty a jejich pouľití | |
| KR20060123364A (ko) | 니코틴성 아세틸콜린 수용체 리간드 | |
| AU2021300831B2 (en) | RIP1k inhibitors | |
| KR20070090922A (ko) | 니코틴성 아세틸콜린 수용체 리간드 | |
| KR20060009899A (ko) | 니코틴성 아세틸콜린 수용체의 양성 조절제 | |
| RU2369600C1 (ru) | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| SK113399A3 (en) | Quinoxalinediones | |
| CN100445285C (zh) | 烟碱性乙酰胆碱受体配体 | |
| KR20070086273A (ko) | 니코틴성 아세틸콜린 수용체 리간드 | |
| Deligia et al. | Design of novel 3, 6-diazabicyclo [3.1. 1] heptane derivatives with potent and selective affinities for α4β2 neuronal nicotinic acetylcholine receptors | |
| KR20060125812A (ko) | 니코틴성 아세틸콜린 수용체 리간드 | |
| JP2007515481A (ja) | ニコチン性アセチルコリンレセプターリガンド | |
| JP2007506723A (ja) | 非アミド性ノナン | |
| AU2004291456A1 (en) | 5-substituted imidazoles | |
| KR20070020445A (ko) | 알파 7 니코틴성 아세틸콜린 수용체를 위한 신규한2-(1-아자-비시클로[2.2.2]옥트-3-일)-2,3-디히드로이소인돌-1-온/5,6-디히드로-푸로[2,3-ｃ]피롤-4-온 유도체리간드 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060621 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |